This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Relationship to Corticosteroid Therapy

Micha Abeles, MD; Jeffery D. Urman, MD; Naomi F. Rothfield, MD

Arch Intern Med. 1978;138(5):750-754.

Abstract
The relationship of corticosteroid therapy to the development of aseptic necrosis (AN) in 365 patients with systemic lupus erythematosus (SLE) was investigated. Seventeen patients (4.7%) were identified as having AN. The dosage of corticosteroids ingested during the initial period of therapy in patients with AN was tabulated and compared with that of 25 SLE control patients. There was a substantially greater dose of costicosteroids ingested in the first one, three, and six months of therapy in the patients with AN than in the control SLE group. Severity of disease and duration of therapy were not found to correlate with AN. Total corticosteroid dose was virtually identical in both groups. Thus, high initial corticosteroid dosages in patients with SLE seem to be associated with the development of AN.

(Arch Intern Med 138:750-754, 1978)

Author Affiliations
From the Division of Rheumatic Diseases, University of Connecticut School of Medicine, Farmington.

Footnotes
Accepted for publication June 7, 1977.

Reprint requests to Division of Rheumatic Diseases, University of Connecticut School of Medicine, Farmington, CT 06032 (Dr Abeles).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Femoral head osteonecrosis can be caused by disruption of the systemic immune response via the toll-like receptor 4 signalling pathway
Okazaki et al.
Rheumatology (Oxford) 2009;48:227-232.
ABSTRACT | FULL TEXT  

Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus
Fialho et al.
Lupus 2007;16:239-244.
ABSTRACT  

The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients
Prasad et al.
Lupus 2007;16:157-162.
ABSTRACT  

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study
Calvo-Alen et al.
Ann Rheum Dis 2006;65:785-790.
ABSTRACT | FULL TEXT  

Treatment of lupus with corticosteroids
Chatham and Kimberly
Lupus 2001;10:140-147.
ABSTRACT  

Atraumatic Osteonecrosis of the Knee
Mont et al.
JBJS 2000;82:1279-1279.
ABSTRACT | FULL TEXT  

Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: Is there a role for antiphospholipid antibodies?
Mok et al.
Ann Rheum Dis 2000;59:462-467.
ABSTRACT | FULL TEXT  

Review : Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?
Rascu et al.
Lupus 1996;5:323-327.
ABSTRACT  

High-Dose Intravenous Methylprednisolone Therapy Associated with Osteonecrosis in Patients with Systemic Lupus Erythematosus
Massardo et al.
Lupus 1992;1:401-405.
ABSTRACT  

Fat Embolism in Sickle Cell Disease: Report of a Case With Brief Review of the Literature
Shapiro and Hayes
Arch Intern Med 1984;144:181-182.
ABSTRACT